Aeglea BioTherapeutics, Inc.
Aeglea BioTherapeutics, Inc. (AGLE) is a publicly traded company in the Unknown sector. Across all available filings, 19 corporate insiders have executed 87 transactions totaling $13.6M, demonstrating a bullish sentiment with $10.7M in net insider flow. The most recent transaction on Nov 24, 2023 involved a transaction of 723,440 shares valued at $0.
AGLE Insider Activity Summary
Who Is Buying AGLE Stock?
No significant insider buying has been recorded for AGLE in the recent period.
Who Is Selling AGLE Stock?
No significant insider selling has been recorded for AGLE in the recent period.
Is Aeglea BioTherapeutics, Inc. Insider Trading Bullish or Bearish?
Based on recent SEC filings, insider sentiment for AGLE is bullish with an Insider Alignment Score of 90/100 and a net flow of $10.7M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
AGLE Frequently Asked Questions
Understanding AGLE Insider Activity
Insider trading at Aeglea BioTherapeutics, Inc. (AGLE) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 19 insiders are actively trading AGLE stock, having executed 87 transactions in the past 90 days. The most active insider is Eli &. Co Lilly (Executive), who has made 2 transactions totaling $5.0M.
Related Tools
Track Aeglea BioTherapeutics, Inc. Insider Activity
Get notified when executives and directors at AGLE file new Form 4 transactions